

CITATION REPORT

List of articles citing

Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis

DOI: 10.1111/j.1365-2036.2006.02927.x

Alimentary Pharmacology and Therapeutics, 2006, 23, 1567-7

Source: <https://exaly.com/paper-pdf/40425873/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
365	Probiotics and prebiotics in chronic inflammatory bowel diseases. 2006 , 12, 5941-50		113
364	The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. 2006 , 8, 486-98		37
363	Probiotics in the Management of Inflammatory Bowel Diseases?. <i>American Journal of Gastroenterology</i> , 2007 , 102, S22-S28	0.7	3
362	Probiotics, prebiotics, and inflammatory bowel disease. 2007 , 90-116		1
361	Bibliography. Current world literature. Esophagus. 2007 , 23, 479-90		
360	Development of new probiotics by strain combinations: is it possible to improve the adhesion to intestinal mucus?. 2007 , 90, 2710-6		55
359	Prebiotics, probiotics, and dietary fiber in gastrointestinal disease. 2007 , 36, 47-63, v		50
358	Gut microbiota: mining for therapeutic potential. 2007 , 5, 274-84		97
357	[Probiotics and prebiotics in inflammatory bowel disease]. 2007 , 30, 419-25		1
356	Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. 2007 , 66, 307-15		141
355	Use of probiotics for prevention of radiation-induced diarrhea. 2007 , 13, 912-5		181
354	Effects of budesonide and probiotics enemas on the colonic mucosa of rats with experimental colitis. 2007 , 22, 34-8		3
353	Probiotics in the management of colonic disorders. 2007 , 9, 434-40		18
352	Microbial host interactions in IBD: implications for pathogenesis and therapy. 2007 , 9, 497-507		87
351	A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. 2008 , 53, 2524-31		143
350	Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease?. 2008 , 52, 906-12		27
349	Probiotic <i>Lactobacillus reuteri</i> suppress proinflammatory cytokines via c-Jun. 2008 , 14, 1068-83		168

348	Role of probiotic therapy in IBD. 2008 , 14, 1597-605	70
347	Isolation of lactobacilli with probiotic properties from the human stomach. 2008 , 47, 269-74	47
346	Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. 2008 , 151, 528-35	257
345	Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. 2008 , 65, 453-67	100
344	Commercially Available Human Probiotic Microorganisms. 2008 , 441-532	0
343	European evidence-based Consensus on the management of ulcerative colitis: Current management. 2008 , 2, 24-62	37 ¹
342	An experimental study on ulcerative colitis as a potential target for probiotic therapy by Lactobacillus acidophilus with or without "olsalazine". 2008 , 2, 296-303	21
341	Probiotics and immunology: separating the wheat from the chaff. 2008 , 29, 565-73	74
340	Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases. 2008 , 14, 1585-96	224
339	Dietary supplements commonly used for prevention. 2008 , 35, 749-67	12
338	Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease. 2008 , 12, 301-12	16
337	Alarm im Darm. 2008 , 33, S39-S43	
336	Probiotics for maintenance of remission in ulcerative colitis. 2008 ,	2
335	Manipulation of intestinal microbial flora for therapeutic benefit in inflammatory bowel diseases: review of clinical trials of probiotics, pre-biotics and synbiotics. 2008 , 3, 167-84	29
334	Effect of acute mucosal exposure to Lactobacillus rhamnosus GG on human colonic smooth muscle cells. 2008 , 42 Suppl 3 Pt 2, S185-90	29
333	Probiotics in the treatment of human inflammatory bowel diseases: update 2008. 2008 , 42 Suppl 2, S97-103	25
332	Probiotics for the prevention of nosocomial pneumonia: current evidence and opinions. 2008 , 14, 168-75	24
331	Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells. 2008 , 14, 2511-6	122

330	Treatment of inflammatory bowel disease: a review of medical therapy. 2008 , 14, 354-77	163
329	[Probiotics in gastrointestinal disorders]. 2009 , 150, 883-94	0
328	Ulcerative colitis: current treatment strategies and future prospects. 2009 , 2, 99-108	39
327	Identification of a Gene Cluster for the Biosynthesis of a Long, Galactose-Rich Exopolysaccharide in <i>Lactobacillus rhamnosus</i> GG and Functional Analysis of the Priming Glycosyltransferase. 2009 , 75, 3554-63	200
326	Inflammatory disease processes and interactions with nutrition. 2009 , 101 Suppl 1, S1-45	247
325	Diagnostic and treatment algorithms of ulcerative colitis in Ukraine. 2009 , 27, 550-4	1
324	The gut microbiota in inflammatory bowel disease. 2009 , 15, 1528-36	78
323	Probiotics for inflammatory bowel disease: a critical appraisal. 2009 , 27 Suppl 1, 111-4	7
322	The therapeutic impact of manipulating microbiota in inflammatory bowel disease. 2009 , 15, 2074-86	24
321	Probiotics in pediatric inflammatory bowel diseases. 2009 , 11, 238-47	2
320	Probiotics and health: a review of the evidence. 2009 , 34, 340-373	55
319	Toll-like receptor and innate cytokine responses induced by lactobacilli colonization and human rotavirus infection in gnotobiotic pigs. 2009 , 127, 304-15	39
318	Intestinal bacteria and inflammatory bowel disease. 2009 , 46, 25-54	67
317	<i>Lactobacillus rhamnosus</i> alleviates intestinal barrier dysfunction in part by increasing expression of zonula occludens-1 and myosin light-chain kinase in vivo. 2009 , 92, 2400-8	89
316	Gastrointestinal drugs. 2009 , 573-587	
315	Administration of a synbiotic to free-living elderly and evaluation of serum cytokines. A pilot study. 2010 , 16, 854-8	30
314	ALIMENTOS PROBIÓTICOS EN CHILE: ¿QUÉ CEPAS Y QUÉ PROPIEDADES SALUDABLES?. 2010 , 37,	6
313	Novel perspectives in probiotic treatment: the efficacy and unveiled mechanisms of the physiological functions. 2010 , 3, 117-27	6

312	Probiotic for new onset ulcerative colitis in children: baby's got bac(ter)ia. 2010 , 16, 177-8	
311	Impact of lipoteichoic acid modification on the performance of the probiotic <i>Lactobacillus rhamnosus</i> GG in experimental colitis. 2010 , 162, 306-14	74
310	Consensus guidelines for the management of inflammatory bowel disease. 2010 , 47, 313-25	23
309	Probiotic Treatment of Colitis in Animal Models and People. 2010 , 571-587	
308	Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. 2010 , 16, 1908-15	85
307	Use of probiotics in gastrointestinal disorders: what to recommend?. 2010 , 3, 307-19	146
306	Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome. 2010 , 140, 690S-7S	72
305	Probiotics in gastrointestinal disorders. 2010 , 38, 122-9	15
304	Probiotics for maintaining remission of ulcerative colitis in adults. 2010 , 44, 565-71	20
303	Recent developments and perspectives in the investigation of probiotic effects. 2010 , 300, 3-10	70
302	Inflammatory bowel disease, gut bacteria and probiotic therapy. 2010 , 300, 25-33	109
301	[Microbiota and probiotics: effects on human health]. 2010 , 56, 611-50	10
300	Probiotics and Prebiotics. 2010 , 205-227	9
299	Probiotics for maintenance of remission in ulcerative colitis. 2011 , CD007443	71
298	Effect of food models and low-temperature storage on the adhesion of <i>Lactobacillus rhamnosus</i> GG to Caco-2 cells. 2011 , 59, 8661-6	235
297	A randomised double-blind placebo-controlled trial with <i>Lactobacillus acidophilus</i> La-5 and <i>Bifidobacterium animalis</i> subsp. <i>lactis</i> BB-12 for maintenance of remission in ulcerative colitis. 2011 , 5, 115-21	93
296	Gut microbiota and inflammation. <i>Nutrients</i> , 2011 , 3, 637-82	6.7 264
295	Nutritional modulation of the inflammatory bowel response. 2011 , 84, 89-101	21

294	Development of T cell subset responses in gnotobiotic pigs infected with human rotaviruses and colonized with probiotic lactobacilli. 2011 , 141, 267-75		20
293	Probiotics in inflammatory bowel diseases and associated conditions. <i>Nutrients</i> , 2011 , 3, 245-64	6.7	51
292	Probiotics in the treatment of human inflammatory bowel diseases: update 2011. 2011 , 45 Suppl, S139-44		64
291	Current and Future Applications of Probiotics. 2011 , 7, 170-180		2
290	Indications for the use of probiotics in gastrointestinal diseases. 2011 , 29, 574-87		44
289	Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. 2011 , 60, 1050-9		228
288	Probiotiques et maladies inflammatoires cryptogébiques de l'intestin. 2011 , 9, 113-116		
287	Encapsulation of probiotic living cells: From laboratory scale to industrial applications. 2011 , 104, 467-483		528
286	Malt in combination with <i>Lactobacillus rhamnosus</i> increases concentrations of butyric acid in the distal colon and serum in rats compared with other barley products but decreases viable counts of cecal bifidobacteria. 2011 , 141, 101-7		18
285	Inflammatory Bowel Disease. 2011 ,		2
284	In vitro fermentation of sugar beet arabino-oligosaccharides by fecal microbiota obtained from patients with ulcerative colitis to selectively stimulate the growth of <i>Bifidobacterium</i> spp. and <i>Lactobacillus</i> spp. 2011 , 77, 8336-44		55
283	Nutrients and gut health. 2011 , 84, 85-8		1
282	Is 5-ASA still the treatment of choice for ulcerative colitis?. 2011 , 12, 1396-405		20
281	Probiotics, nuclear receptor signaling, and anti-inflammatory pathways. 2011 , 2011, 971938		44
280	The Impact of Gut Microbiota in Human Health and Diseases: Implication for Therapeutic Potential. 2011 , 19, 155-173		3
279	[Probiotics in gastrointestinal diseases]. 2012 , 101, 1077-85		
278	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. 2012 , 10, CD000544		101
277	Ernährung bei chronisch entzündlichen Darmerkrankungen (CED). 2012 , 37, 349-362		2

276	Gastrointestinal microbiota and some children diseases: a review. 2012 , 2012, 676585	26
275	Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. 2012 , 55, 340-61	265
274	Gram-negative bacteria account for main differences between faecal microbiota from patients with ulcerative colitis and healthy controls. <i>Beneficial Microbes</i> , 2012 , 3, 287-97	4.9 68
273	Probiotics and oral health. 2012 , 18, 5522-31	34
272	Probiotic Nondairy Beverages. 2012 , 707-728	4
271	Nutritional and probiotic supplementation in colitis models. 2012 , 57, 2786-810	25
270	Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease. 2012 , 41, 821-42	20
269	Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. 2012 , 72, 803-23	156
268	Bacterial flora as a cause or treatment of chronic diarrhea. 2012 , 41, 581-602	14
267	Characterization of a probiotic-derived soluble protein which reveals a mechanism of preventive and treatment effects of probiotics on intestinal inflammatory diseases. 2012 , 3, 25-8	59
266	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. 2012 , 6, 991-1030	715
265	Prophylactic effect of probiotics on the development of experimental autoimmune myasthenia gravis. 2012 , 7, e52119	32
264	Sepsis, the Liver and the Gut. 2012 ,	
263	[Guidelines for the management of ulcerative colitis]. 2012 , 59, 118-40	25
262	[Anti-inflammatory mechanism of <i>Lactobacillus rhamnosus</i> GG in lipopolysaccharide- stimulated HT-29 cell]. 2012 , 60, 86-93	15
261	Microbial translocation across the GI tract. 2012 , 30, 149-73	294
260	Probiotics for the treatment of inflammatory bowel disease. 2012 , 14, 324-33	80
259	Protective effects of cathelicidin-encoding <i>Lactococcus lactis</i> in murine ulcerative colitis. 2012 , 27, 1205-12	44

258	Any role for probiotics in the therapy or prevention of autoimmune diseases? Up-to-date review. 2013 , 10,	9
257	An overview of the last advances in probiotic and prebiotic field. 2013 , 50, 1-16	279
256	Might patients with immune-related diseases benefit from probiotics?. 2013 , 29, 583-6	29
255	Mucosal immunity in human and simian immunodeficiency lentivirus infections. 2013 , 6, 657-65	49
254	A Lactobacillus rhamnosus GG-derived soluble protein, p40, stimulates ligand release from intestinal epithelial cells to transactivate epidermal growth factor receptor. 2013 , 288, 30742-30751	89
253	Ulcerative colitis: prevention of relapse. 2013 , 7, 341-51	10
252	Manipulating the Indigenous Microbiota in Humans: Prebiotics, Probiotics, and Synbiotics. 2013 , 315-338	2
251	Probiotics and clinical effects: is the number what counts?. 2013 , 25, 193-212	41
250	RETRACTED: Preventative and Therapeutic Role of Probiotics in Various Allergic and Autoimmune Disorders: An Up-to-Date Literature Review of Essential Experimental and Clinical Data. 2013 , 18, 121-151	2
249	Gut barrier dysfunction and microbial translocation in cancer cachexia: a new therapeutic target. 2013 , 7, 361-7	55
248	Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. 2013 , 2013, 435268	116
247	Microbiotas from UC patients display altered metabolism and reduced ability of LAB to colonize mucus. 2013 , 3, 1110	30
246	Actual concept of "probiotics": is it more functional to science or business?. 2013 , 19, 1527-40	38
245	Gut microbiota, probiotics, and human health. 2013 , 32, 81-91	24
244	Effects of probiotics and prebiotics in ulcerative colitis. 2013 , 114, 540-3	5
243	Integrative Therapies and Pediatric Inflammatory Bowel Disease: The Current Evidence. 2014 , 1, 149-65	5
242	Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. 2014 , 20, 11505-24	123
241	Activation of epidermal growth factor receptor mediates mucin production stimulated by p40, a Lactobacillus rhamnosus GG-derived protein. 2014 , 289, 20234-44	83

240	Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation?. 2014 , 73, 490-7	30
239	Maintenance of Remission in Ulcerative Colitis. 2014 , 417-430	1
238	Amelioration of colitis in mouse model by exploring antioxidative potentials of an indigenous probiotic strain of <i>Lactobacillus fermentum</i> Lf1. 2014 , 2014, 206732	31
237	S3-Leitlinie der Deutschen Gesellschaft für Ernährungsmedizin (DGEM) in Zusammenarbeit mit der Gesellschaft für klinische Ernährung der Schweiz (GESKES), der Österreichischen Arbeitsgemeinschaft für klinische Ernährung (AKE) und der Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). 2014 , 39, e72-e98	16
236	Isolation of <i>Enterococcus faecium</i> NM113, <i>Enterococcus faecium</i> NM213 and <i>Lactobacillus casei</i> NM512 as novel probiotics with immunomodulatory properties. 2014 , 58, 559-69	15
235	Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. 2014 , 20, 21-35	260
234	Probiotics, Prebiotics, and Antibiotics for Ulcerative Colitis. 2014 , 209-220	
233	Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. 2014 , 7, 473-87	192
232	Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials. 2014 , 7, 1-13	50
231	Increased proportions of <i>Bifidobacterium</i> and the <i>Lactobacillus</i> group and loss of butyrate-producing bacteria in inflammatory bowel disease. 2014 , 52, 398-406	242
230	The immunomodulatory effect of probiotics beyond atopy: an update. 2014 , 51, 320-32	29
229	Randomised clinical trial: <i>Lactobacillus GG</i> modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1113-25	6.1 176
228	Bacillus Probiotics and Biologicals for Improving Animal and Human Health: Current Applications and Future Prospects. 2014 , 360-381	2
227	Use of probiotics and prebiotics in inflammatory bowel disease. 2014 , 81-103	
226	Inflammatory Bowel Disease. 2015 , 347-374	
225	The Mucosal Immune System and Gastrointestinal Inflammation. 2015 , 284-316	
224	Probiotics in the Management of Ulcerative Colitis. 2015 , 49 Suppl 1, S50-5	39
223	Kefir treatment ameliorates dextran sulfate sodium-induced colitis in rats. 2015 , 21, 13020-9	13

222	An Integrated Outlook on the Metagenome and Metabolome of Intestinal Diseases. 2015 , 3, 341-359		5
221	Detection and Identification of Probiotic <i>Lactobacillus plantarum</i> Strains by Multiplex PCR Using RAPD-Derived Primers. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 25141-53	6.3	23
220	Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 20841-58	6.3	66
219	The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. 2015 , 2015, 505878		185
218	Breakthrough <i>Lactobacillus rhamnosus</i> GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis: case report and review of the literature. 2015 , 43, 777-81		57
217	Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. 2015 , 30, 747-59		21
216	Beneficial Effects of Probiotics, Prebiotics, Synbiotics, and Psychobiotics in Inflammatory Bowel Disease. 2015 , 21, 1674-82		102
215	Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches. 2015 , 13, 105-20		80
214	<i>Lactobacillus</i> -produced exopolysaccharides and their potential health benefits: a review. <i>Beneficial Microbes</i> , 2015 , 6, 457-71	4.9	53
213	The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. 2015 , 149, 191-212		110
212	Polyphosphate, an active molecule derived from probiotic <i>Lactobacillus brevis</i> , improves the fibrosis in murine colitis. 2015 , 166, 163-75		26
211	The gut microbiota and inflammatory bowel disease. 2015 , 37, 47-55		392
210	Intestinales Mikrobiom und chronisch-entzündliche Darmerkrankungen: Feindschaft oder Freundschaft?. 2015 , 10, 87-101		2
209	Reviewing clinical studies of probiotics as dietary supplements: probiotics for gastrointestinal disorders, <i>Helicobacter</i> eradication, lactose malabsorption and inflammatory bowel disease (IBD). 2015 , 171-197		
208	Role of the Gut Microbiota in Maintaining GI Health: Highlights on Inflammatory Bowel Disease. 2015 , 261-310		
207	[Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]. 2015 , 80, 32-73		4
206	Diet therapy for inflammatory bowel diseases: The established and the new. 2016 , 22, 2179-94		88
205	Modulation of microbiota as treatment for intestinal inflammatory disorders: An update. 2016 , 22, 7186-202		50

204	Beneficial Properties of Probiotics. 2016 , 27, 73-90		84
203	Probiotics: A Comprehensive Review of Their Classification, Mode of Action and Role in Human Nutrition. 2016 ,		19
202	Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	43
201	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. 2016 , CD000544		60
200	Health Benefits of Probiotic Consumption. 2016 , 163-183		2
199	Comparison of maintenance effect of probiotics and aminosalicylates on ulcerative colitis: A meta-analysis of randomized controlled trials. 2016 , 2, 34-41		3
198	Efficacy of probiotic treatment with <i>Bifidobacterium longum</i> 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. 2016 , 28, 67-74		94
197	Specific probiotic dietary supplementation leads to different effects during remission and relapse in murine chronic colitis. <i>Beneficial Microbes</i> , 2016 , 7, 205-13	4.9	18
196	The goblet cell-derived mediator RELM- β drives spontaneous colitis in Muc2-deficient mice by promoting commensal microbial dysbiosis. 2016 , 9, 1218-33		53
195	Recombinantly produced banana lectin isoform promotes balanced pro-inflammatory response in the colon. 2016 , 20, 68-78		4
194	Probiotics and prebiotics in ulcerative colitis. 2016 , 30, 55-71		65
193	Prebiotics and Probiotics in Inflammatory Bowel Disease (IBD). 2016 , 131-147		2
192	Nutritional Management of Inflammatory Bowel Diseases. 2016 ,		2
191	Aminosalicylates. 2016 , 242-254		
190	An LGG-derived protein promotes IgA production through upregulation of APRIL expression in intestinal epithelial cells. 2017 , 10, 373-384		63
189	Bariatric surgery attenuates colitis in an obese murine model. 2017 , 13, 661-668		4
188	Review of the role of probiotics in gastrointestinal diseases in adults. 2017 , 40, 417-429		23
187	Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease. 2017 , 8, 238-252		145

186	Intestinal Microbiology and Ecology in Crohn's Disease and Ulcerative Colitis. 2017 , 67-74		1
185	Review of the role of probiotics in gastrointestinal diseases in adults. 2017 , 40, 417-429		14
184	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. 2017 , 11, 769-784		599
183	Probiotics in Inflammatory Bowel Disease. 2017 , 46, 769-782		95
182	Potentially probiotic Lactobacillus strains with anti-proliferative activity induce cytokine/chemokine production and neutrophil recruitment in mice. <i>Beneficial Microbes</i> , 2017 , 8, 615-624-9		17
181	An Overview of Probiotic Research. 2017 , 293-357		1
180	Is beer a source of prebiotics?. 2017 , 123, 361-365		8
179	Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 389-400	6.1	206
178	Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. 2017 , 30, 191-231		41
177	Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. 2017 , 174, 1426-1449		82
176	The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	32
175	Antioxidant Properties of Probiotic Bacteria. <i>Nutrients</i> , 2017 , 9,	6.7	315
174	Evaluation of Probiotic L. rhamnosus GG as a Protective Culture in Sea Buckthorn-Based Beverage. 2017 , 3, 48		10
173	Treatment of Inflammatory Bowel Disease in Ulcerative Colitis. 2017 , 343-354		1
172	Nutritional Interventions in the Patient with Inflammatory Bowel Disease. 2018 , 47, 155-177		40
171	Gut microbiota in the pathogenesis of inflammatory bowel disease. 2018 , 11, 1-10		459
170	Probiotics are a good choice in remission of inflammatory bowel diseases: A meta analysis and systematic review. 2018 , 233, 2091-2103		168
169	Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 26-42	6.1	107

168	Inflammatory Bowel Disease. 2018 , 501-516.e8		4
167	Mucosal adhesion and anti-inflammatory effects of GG in the human colonic mucosa: A proof-of-concept study. 2018 , 24, 4652-4662		22
166	[Updated S3-Guideline Colitis ulcerosa. German Society for Digestive and Metabolic Diseases (DGVS) - AWMF Registry 021/009]. 2018 , 56, 1087-1169		35
165	Microbiome and Diseases: Inflammatory Bowel Diseases. 2018 , 151-174		
164	Oral treatment with Lactobacillus rhamnosus 64 during the early postnatal period improves the health of adult rats with TNBS-induced colitis. 2018 , 48, 92-105		3
163	Lactobacillus rhamnosus and Lactobacillus delbrueckii ameliorate the expression of miR-155 and miR-181a in SLE patients. 2018 , 48, 228-233		8
162	Effectiveness of Multistrain Versus Single-strain Probiotics: Current Status and Recommendations for the Future. 2018 , 52 Suppl 1, Proceedings from t, S35-S40		43
161	Probiotics in Gastroenterology: How Pro Is the Evidence in Adults?. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1125-1136	0.7	27
160	Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids. 2019 , 10, 59-76		56
159	Probiotics for inflammatory bowel diseases: a promising adjuvant treatment. 2019 , 70, 20-29		40
158	Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. 2019 , 8,		217
157	Anti-inflammatory effects of probiotics. 2019 , 259-282		1
156	Saccharomyces boulardii alleviates ulcerative colitis carcinogenesis in mice by reducing TNF- α and IL-6 levels and functions and by rebalancing intestinal microbiota. 2019 , 19, 246		50
155	From the Table to the Tumor: The Role of Mediterranean and Western Dietary Patterns in Shifting Microbial-Mediated Signaling to Impact Breast Cancer Risk. <i>Nutrients</i> , 2019 , 11,	6.7	17
154	Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation. 2019 , 19, 1343-1355		3
153	Naringenin promotes recovery from colonic damage through suppression of epithelial tumor necrosis factor- α production and induction of M2-type macrophages in colitic mice. 2019 , 64, 82-92		10
152	The Efficacy of Probiotics, Prebiotic Inulin-Type Fructans, and Synbiotics in Human Ulcerative Colitis: A Systematic Review and Meta-Analysis. <i>Nutrients</i> , 2019 , 11,	6.7	51
151	First and second generation probiotic therapeutics for Inflammatory Bowel Disease. 2019 , 9, 100159		11

150	The Anti-inflammatory Effects of Dietary Anthocyanins against Ulcerative Colitis. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	49
149	Sex, gut microbiome, and cardiovascular disease risk. 2019 , 10, 29		57
148	Short-term follow-up of intestinal flora in radiation-exposed mice. 2019 , 60, 328-332		6
147	Microbe-metabolite-host axis, two-way action in the pathogenesis and treatment of human autoimmunity. 2019 , 18, 455-475		25
146	European Crohn's and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease. 2019 , 13, 673-685e		38
145	Novel Approaches for Pouchitis and Colitis With or Without Diversion. 2019 , 529-535		1
144	ZS2058 and GG Use Different Mechanisms to Prevent Infection. <i>Frontiers in Microbiology</i> , 2019 , 10, 299	5.7	16
143	Dietary Interventions and Inflammatory Bowel Disease. 2019 , 33-42		
142	Use of Probiotics in Inflammatory Bowel Disease. 2019 , 149-154		
141	Thirty Years of Lactobacillus rhamnosus GG: A Review. 2019 , 53 Suppl 1, S1-S41		90
140	Perinephric Abscess and Bacteremia Due to Lactobacillus Species in a Diabetic Adult. 2019 , 27, 366-369		0
139	Side Effects Associated with Probiotic Use in Adult Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Nutrients</i> , 2019 , 11,	6.7	13
138	Microbial-Based Therapies in the Treatment of Inflammatory Bowel Disease - An Overview of Human Studies. 2018 , 9, 1571		57
137	A novel probiotic, Lactobacillus johnsonii 456, resists acid and can persist in the human gut beyond the initial ingestion period. 2019 , 10, 458-480		19
136	AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. 2019 , 156, 748-764		92
135	AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. 2019 , 156, 769-808.e29		61
134	Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS). 2019 , 57, 162-241		25
133	Difference in Pathomechanism Between Crohn's Disease and Ulcerative Colitis Revealed by Colon Transcriptome. 2019 , 25, 722-731		9

132	The microbiome in threatened species conservation. 2019 , 229, 85-98		96
131	Antibiotics and probiotics in inflammatory bowel disease: when to use them?. 2020 , 11, 62-69		16
130	Perioperative Dietary Therapy in Inflammatory Bowel Disease. 2020 , 14, 431-444		22
129	Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. 2020 , 19, 118-126		151
128	Treatment of murine colitis by <i>Saccharomyces boulardii</i> secreting atrial natriuretic peptide. 2020 , 98, 1675-1687		4
127	Alcohol decreases intestinal ratio of to and induces hepatic immune tolerance in a murine model of DSS-colitis. 2020 , 12, 1-16		4
126	Probiotics in Medicine: A Long Debate. 2020 , 11, 2192		46
125	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. 2020 , 8, CD000544		11
124	Probiotics as a Coadjuvant Factor in Active or Quiescent Inflammatory Bowel Disease of Adults-A Meta-Analytical Study. <i>Nutrients</i> , 2020 , 12,	6.7	4
123	Probiotics: A Dietary Factor to Modulate the Gut Microbiome, Host Immune System, and Gut-Brain Interaction. <i>Microorganisms</i> , 2020 , 8,	4.9	22
122	Gut Microbiota and Intestinal Trans-Epithelial Permeability. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	42
121	Protective effects of tryptophan-catabolizing <i>Lactobacillus plantarum</i> KLDS 1.0386 against dextran sodium sulfate-induced colitis in mice. 2020 , 11, 10736-10747		13
120	Complementary and alternative medications in the management of inflammatory bowel disease. 2020 , 13, 1756284820927550		10
119	Anti-Inflammatory and Gut Microbiota Modulatory Effect of Strain LDTM 7511 in a Dextran Sulfate Sodium-Induced Colitis Murine Model. <i>Microorganisms</i> , 2020 , 8,	4.9	8
118	AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders. 2020 , 159, 708-738.e4		35
117	Probiotics for maintenance of remission in ulcerative colitis. 2020 , 3, CD007443		16
116	The reduction of DSS-induced colitis severity in mice exposed to cigarette smoke is linked to immune modulation and microbial shifts. 2020 , 10, 3829		8
115	<i>Bacillus subtilis</i> RZ001 improves intestinal integrity and alleviates colitis by inhibiting the Notch signalling pathway and activating ATOH-1. 2020 , 78,		10

114	Probiotics for induction of remission in ulcerative colitis. 2020 , 3, CD005573	21
113	Gut Remediation of Environmental Pollutants. 2020 ,	
112	A Specific Strain of Lactic Acid Bacteria, , Inhibits Inflammasome Activation In Vitro and Prevents Inflammation-Related Disorders. 2020 , 205, 811-821	10
111	Disease managing capacities and mechanisms of host effects of lactic acid bacteria. 2021 , 61, 1365-1393	7
110	Scutellaria baicalensis Georgi polysaccharide ameliorates DSS-induced ulcerative colitis by improving intestinal barrier function and modulating gut microbiota. 2021 , 166, 1035-1045	45
109	The effects of probiotics, prebiotics and synbiotics on the reduction of IBD complications, a periodic review during 2009-2020. 2021 , 130, 1823-1838	8
108	Human-Derived Bifidobacterium dentium Modulates the Mammalian Serotonergic System and Gut-Brain Axis. 2021 , 11, 221-248	26
107	Apprehending Ulcerative Colitis Management With Springing Up Therapeutic Approaches: Can Nanotechnology Play a Nascent Role?. 2021 , 9, 9-32	1
106	Anti-Inflammatory and Immunomodulatory Effects of Probiotics in Gut Inflammation: A Door to the Body. 2021 , 12, 578386	61
105	Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis. 2021 , 60, 2855-2875	26
104	Nicotinamide Ameliorates Dextran Sulfate Sodium-Induced Chronic Colitis in Mice through Its Anti-Inflammatory Properties and Modulates the Gut Microbiota. 2021 , 2021, 5084713	1
103	GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade. 2021 ,	21
102	The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010-20. 2021 , 105, 91-104	10
101	Does dairy product consumption impact the prevalence of inflammatory bowel disease? An ecological cross-sectional analysis. 2021 , 80, 104446	1
100	Probiotics, Prebiotics and Synbiotics in Inflammatory Bowel Diseases. 2021 , 10,	17
99	Highlighting the Relevance of Gut Microbiota Manipulation in Inflammatory Bowel Disease. 2021 , 11,	16
98	Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory Bowel Diseases. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3 18
97	Gut mucosal and adipose tissues as health targets of the immunomodulatory mechanisms of probiotics. 2021 , 112, 764-779	1

96	Anthocyanin-containing purple potatoes ameliorate DSS-induced colitis in mice. 2021 , 93, 108616		10
95	Effects of the Aqueous Extract on the Gut Microbiota of Mice with Intestinal Disorders. 2021 , 2021, 4936970		3
94	Recombinant antimicrobial peptide microcin J25 alleviates DSS-induced colitis via regulating intestinal barrier function and modifying gut microbiota. 2021 , 139, 111127		10
93	Selenium-Enriched Ameliorates Dextran Sulfate Sodium-Induced Chronic Colitis in Mice by Regulating Inflammatory Cytokines and Intestinal Microbiota. <i>Frontiers in Medicine</i> , 2021 , 8, 716816	4.9	3
92	GG Derived Extracellular Vesicles Modulate Gut Microbiota and Attenuate Inflammatory in DSS-Induced Colitis Mice. <i>Nutrients</i> , 2021 , 13,	6.7	9
91	ATCC 6475 metabolites upregulate the serotonin transporter in the intestinal epithelium. <i>Beneficial Microbes</i> , 2021 , 12, 583-599	4.9	2
90	Bile Acid-Gut Microbiota Axis in Inflammatory Bowel Disease: From Bench to Bedside. <i>Nutrients</i> , 2021 , 13,	6.7	5
89	Gut microbiota and the immune system and inflammation. 2021 , 311-333		
88	Immunity and Gut Microbiome: Role of Probiotics and Prebiotics. 2021 , 61-83		0
87	Probiotics as Anti-Inflammatory Agents in Inflammatory Bowel Disease and Irritable Bowel Syndrome. 2021 , 123-139		1
86	Probiotics and Chronic Gastrointestinal Disease. 2009 , 949-975		1
85	Anti-inflammatory Effects of Probiotics and Their Metabolites: Possible Role for Epigenetic Effects. 2014 , 127-150		1
84	Prebiotics, Probiotics, Antibiotics, and Nutritional Therapies in IBD. 2011 , 123-150		2
83	Ulcerative Colitis. 2010 , 1975-2013.e9		2
82	Therapeutic applications of probiotics in ulcerative colitis: An updated review. 2020 , 13, 100194		16
81	Escherichia coli strain Nissle 1917 ameliorates experimental colitis by modulating intestinal permeability, the inflammatory response and clinical signs in a faecal transplantation model. 2016 , 65, 201-210		37
80	Surface display of p75, a Lactobacillus rhamnosus GG derived protein, on Bacillus subtilis spores and its antibacterial activity against Listeria monocytogenes. 2020 , 10, 139		3
79	Microbiota-gut-brain axis and its affect inflammatory bowel disease: Pathophysiological concepts and insights for clinicians. 2020 , 8, 1013-1025		22

78	Probiotic sonicates selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinase. 2011 , 6, e16953	19
77	The intestinal microbiota plays a role in Salmonella-induced colitis independent of pathogen colonization. 2011 , 6, e20338	120
76	Different Effects of Three Selected Lactobacillus Strains in Dextran Sulfate Sodium-Induced Colitis in BALB/c Mice. 2016 , 11, e0148241	20
75	Microbiome, gut dysbiosis and inflammatory bowel disease: That moment when the function is more important than taxonomy. 2018 , 46, 396-425	16
74	Nutritional Support and Probiotics as a Potential Treatment of IBD. 2020 , 21, 1417-1427	2
73	Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?. 2020 , 15, 216-233	13
72	Effect of probiotic Lactobacillus rhamnosus GG intervention on global serum lipidomic profiles in healthy adults. 2008 , 14, 3188-94	54
71	Targeting intestinal microflora in inflammatory bowel disease. 2006 , 12, 7225-6	2
70	Enteric microbiota leads to new therapeutic strategies for ulcerative colitis. 2014 , 20, 15657-63	35
69	VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice. 2018 , 24, 4254-4262	47
68	Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease?. 2014 , 5, 550-9	49
67	Guidelines for the Management of Ulcerative Colitis. 2012 , 10, 1	9
66	Probiotics in inflammatory bowel disease: Pathophysiological background and clinical applications. 2013 , 3, 31	7
65	The Mechanisms of Immune System Regulation by Probiotics in Immune-Related Diseases. <i>Journal of Pharmacy and Nutrition Sciences (discontinued)</i> , 2016 , 6, 105-111	0.3 2
64	Probiotics in the Management of Inflammatory Bowel Diseases?. <i>American Journal of Gastroenterology</i> , 2007 , 102, 22-28	0.7
63	Probiotics in Ulcerative Colitis. 2009 , 181-194	
62	Probiotics and prebiotics in the management of ulcerative colitis. <i>Food Science and Technology Bulletin</i> , 2009 , 5, 93-102	
61	Probiotics and Prebiotics as Nutraceuticals. 2009 , 223-242	

60 Probiotics and Inflammatory Immune Responses. **2010**, 591-610

59 Probiotic Therapy. **2013**, 313-323

58 Probiotics. **2013**, 979-994

2

57 Pathophysiological responses from human gut microbiome. *World Journal of Translational Medicine*, **2014**, 3, 133

8

56 Probiotics in Gastrointestinal Diseases. 255-269

55 The application of probiotics for the treatment of inflammatory bowel diseases, hepatopathy, and infectious diseases. *Russian Journal of Evidence-Based Gastroenterology*, **2017**, 6, 35

0.3

54 Probiotic Therapy. **2017**, 357-367

53 15 Inflammatory Bowel Disease. **2017**, 347-374

52 Microbes in the Pathogenesis of Inflammatory Bowel Disease: A Review. **2019**, 399-410

51 Efficacy and safety of probiotics in adults with ulcerative colitis: A meta-analysis of placebo-controlled trials. *World Chinese Journal of Digestology*, **2019**, 27, 367-375

0.1

50 Environmental Pollutants that Can Be Metabolized by the Host, but Would Be Harmful to Humans (e.g., Causing Cancers, etc.). **2020**, 169-198

49 Probiotics and Their Metabolites Ameliorate Inflammatory Bowel Disease: A Critical Review. *Infectious Microbes & Diseases*, **2021**, 3, 4-13

1.3

1

48 Probiotics. **2020**, 809-822.e5

47 Innate Cytokine Responses and Toll-Like Receptor Induced by Recombinant Porcine Rotavirus VP6 and VP7 Proteins Expressing in *Lactobacillus plantarum* NC8 Strain Colonization in Mice. *World Journal of Vaccines*, **2020**, 10, 17-31

0.4

46 Probiotic Therapy. **2008**, 351-361

45 The emerging therapeutic role of probiotics in inflammatory bowel disease. *Gastroenterology and Hepatology*, **2008**, 4, 634-40

0.7

3

44 Probiotics, prebiotics, synbiotics and naturally fermented foods: why more may be more. *Annals of Gastroenterology*, **2013**, 26, 277-278

2.2

3

43 Gut bacteria in health and disease. *Gastroenterology and Hepatology*, **2013**, 9, 560-9

0.7

101

42	The Use of Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2018 , 14, 415-425	0.7	11
41	Probiotics: current regulatory aspects of probiotics for use in different disease conditions. 2022 , 465-499		
40	Gut Microbial Metabolite-Mediated Regulation of the Intestinal Barrier in the Pathogenesis of Inflammatory Bowel Disease.. <i>Nutrients</i> , 2021 , 13,	6.7	1
39	Probiotics as Edible Vaccines. 2022 , 269-293		
38	Probiotics and intestinal health. 2022 , 343-353		
37	Therapeutic applications of probiotics and its regulatory framework. 2022 , 635-665		
36	The as a Probiotic: Focusing on Liver Diseases.. <i>Microorganisms</i> , 2022 , 10,	4.9	1
35	Lactocaseibacillus rhamnosus modulates the inflammatory response and the subsequent lung damage in a murine model of acute lung inflammation.. <i>Clinics</i> , 2022 , 77, 100021	2.3	0
34	Modulation of the gut microbiota: opportunities and regulatory aspects.. <i>Minerva Gastroenterology</i> , 2022 ,	3	0
33	Lactobacillus and intestinal diseases: Mechanisms of action and clinical applications.. <i>Microbiological Research</i> , 2022 , 260, 127019	5.3	1
32	A Brief Overview on Probiotics: The Health Friendly Microbes. <i>Biomedical and Pharmacology Journal</i> , 2021 , 14, 1869-1880	0.9	0
31	A Rapid Screening Method of Candidate Probiotics for Inflammatory Bowel Diseases and the Anti-inflammatory Effect of the Selected Strain XY1.. <i>Frontiers in Microbiology</i> , 2021 , 12, 760385	5.7	1
30	The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies.. <i>Frontiers in Medicine</i> , 2021 , 8, 766126	4.9	3
29	Dysbiosis in Inflammatory Bowel Disease: Pathogenic Role and Potential Therapeutic Targets.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	7
28	Functional Foods and Antioxidant Effects: Emphasizing the Role of Probiotics.		
27	Trends in Probiotics on Human Health and Industrial Application. 2022 , 237-248		
26	Factors Affecting Spontaneous Endocytosis and Survival of Probiotic Lactobacilli in Human Intestinal Epithelial Cells. <i>Microorganisms</i> , 2022 , 10, 1142	4.9	
25	Pharmacokinetic and gut microbiota analyses revealed the effect of Lactobacillus acidophilus on the metabolism of Olsalazine in ulcerative colitis rats. <i>European Journal of Pharmaceutical Sciences</i> , 2022 , 175, 106235	5.1	

24	Sanhuang Xiexin decoction ameliorates DSS-induced colitis in mice by regulating intestinal inflammation, intestinal barrier, and intestinal flora. <i>Journal of Ethnopharmacology</i> , 2022 , 115537	5	○
23	Role of gastrointestinal microbial populations, a terra incognita of the human body in the management of intestinal bowel disease and metabolic disorders. <i>Beneficial Microbes</i> , 1-24	4.9	○
22	Novel genetic modules encoding high-level antibiotic-free protein expression in probiotic lactobacilli.		○
21	Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches. 2022 , 10, 2236		1
20	Protective effect of <i>Limosilactobacillus fermentum</i> HFY06 on dextran sulfate sodium-induced colitis in mice. 13,		○
19	<i>Lactobacillus rhamnosus</i> sepsis, endocarditis and septic emboli in a patient with ulcerative colitis taking probiotics. 2022 , 15, e249020		○
18	The emerging microbiome based approaches to IBD therapy: From SCFAs to urolithin A.		○
17	A probiotic bi-functional peptidoglycan hydrolase sheds NOD2 ligands to regulate gut homeostasis.		○
16	Probiotics and gastrointestinal diseases.		○
15	Valorization of leftover green tea residues through conversion to bioactive peptides using probiotics-aided anaerobic digestion.		○
14	Innovative, complementary and alternative therapy in inflammatory bowel diseases: A broad 2020s update. 1,		○
13	PROBIOTYKI A ZDROWIE - DZIŃ JUTRO. 2017 , 15, 86-94		○
12	Polyphenols and inflammatory bowel disease: Natural products with therapeutic effects?. 1-24		1
11	Membrane Vesicles Derived from Gut Microbiota and Probiotics: Cutting-Edge Therapeutic Approaches for Multidrug-Resistant Superbugs Linked to Neurological Anomalies. 2022 , 14, 2370		2
10	Impact of Total Parenteral Nutrition on Gut Microbiota in Pediatric Population Suffering Intestinal Disorders. 2022 , 14, 4691		○
9	Design of a self-driven probiotic-CRISPR/Cas9 nanosystem for sono-immunometabolic cancer therapy. 2022 , 13,		○
8	Stable colonization of <i>Akkermansia muciniphila</i> educates host intestinal microecology and immunity to battle against inflammatory intestinal diseases.		1
7	ESPEN guideline on Clinical Nutrition in inflammatory bowel disease. 2023 ,		3

- 6 Modulation of intestinal microbiome: Promising therapies in the treatment of inflammatory bowel disease. **2023**, 57-68
- 5 Fermented foods, prebiotics, and probiotics. **2023**, 239-263
- 4 Bioinspired oral delivery devices. **2023**, 1, 208-225
- 3 The Potential Therapeutic Role of Lactobacillaceae rhamnosus for Treatment of Inflammatory Bowel Disease. **2023**, 12, 692
- 2 Translation of Immunomodulatory Effects of Probiotics into Clinical Practice.
- 1 Pathogenesis: Crohn's disease and ulcerative colitis. **2023**, 9-46